A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,131

Participants

Timeline

Start Date

August 13, 2019

Primary Completion Date

May 25, 2026

Study Completion Date

May 25, 2026

Conditions
Psoriatic Arthritis
Interventions
DRUG

Bimekizumab

Subjects will receive bimekizumab at pre-specified time-points.

Trial Locations (138)

10029

Pa0012 50011, New York

11201

Pa0012 50010, Brooklyn

14642

Pa0012 50034, Rochester

16635

Pa0012 50020, Duncansville

19610

Pa0012 50006, Wyomissing

21740

Pa0012 50015, Hagerstown

25801

Pa0012 50050, Beckley

28144

Pa0012 50031, Salisbury

28211

Pa0012 50125, Charlotte

29118

Pa0012 50007, Orangeburg

30342

Pa0012 50039, Atlanta

33613

Pa0012 50037, Tampa

34684

Pa0012 50033, Palm Harbor

38305

Pa0012 50001, Jackson

40504

Pa0012 50028, Lexington

45377

Pa0012 50040, Vandalia

48911

Pa0012 50019, Lansing

63141

Pa0012 50016, St Louis

70836

Pa0012 50023, Baton Rouge

75150

Pa0012 50036, Mesquite

76710

Pa0012 50009, Waco

78404

Pa0012 50049, Corpus Christi

78731

Pa0012 50002, Austin

83702

Pa0012 50024, Boise

85037

Pa0012 50017, Phoenix

87102

Pa0012 50029, Albuquerque

92128

Pa0012 50035, San Diego

02115-5817

Pa0012 50047, Boston

07728

Pa0012 50005, Freehold

02919

Pa0012 50008, Johnston

38119-5214

Pa0012 50012, Memphis

Unknown

Pa0012 30005, Camberwell

Pa0012 30002, Clayton

Pa0012 30008, Hobart

Pa0012 30003, Maroochydore

Pa0012 30007, Victoria Park

Pa0012 30006, Woodville South

Pa0012 40003, Genk

Pa0012 40002, Leuven

Pa0012 40059, Mons

Pa0012 50041, Québec

Pa0012 50042, Rimouski

Pa0012 50043, Sydney

Pa0012 50044, Trois-Rivières

Pa0012 40061, Brno

Pa0012 40065, Brno

Pa0012 40062, Moravska Ostrava A Privoz

Pa0012 40009, Pardubice

Pa0012 40013, Prague

Pa0012 40014, Prague

Pa0012 40015, Prague

Pa0012 40063, Prague

Pa0012 40066, Prague

Pa0012 40010, Uherské Hradiště

Pa0012 40012, Zlín

Pa0012 40068, Chambray-lès-Tours

Pa0012 40019, Paris

Pa0012 40074, Bad Doberan

Pa0012 40025, Berlin

Pa0012 40076, Cottbus

Pa0012 40023, Erlangen

Pa0012 40117, Frankfurt

Pa0012 40029, Hamburg

Pa0012 40071, Hamburg

Pa0012 40027, Herne

Pa0012 40078, Leipzig

Pa0012 40026, Ratingen

Pa0012 40081, Budapest

Pa0012 40083, Budapest

Pa0012 40032, Debrecen

Pa0012 40030, Eger

Pa0012 40082, Kistarcsa

Pa0012 40079, Szentes

Pa0012 40033, Székesfehérvár

Pa0012 40084, Catania

Pa0012 40087, Milan

Pa0012 40086, Reggio Emilia

Pa0012 20035, Bunkyō City

Pa0012 20030, Chūōku

Pa0012 20043, Itabashi-ku

Pa0012 20036, Kawachi-Nagano

Pa0012 20045, Kita-gun

Pa0012 20049, Kitakyushu

Pa0012 20044, Minatoku

Pa0012 20033, Nagoya

Pa0012 20041, Osaka

Pa0012 20046, Osaka

Pa0012 20048, Saitama

Pa0012 20031, Sapporo

Pa0012 20042, Sasebo

Pa0012 20032, Suita

Pa0012 40093, Bialystok

Pa0012 40119, Bydgoszcz

Pa0012 40038, Elblag

Pa0012 40088, Elblag

Pa0012 40096, Gdynia

Pa0012 40042, Krakow

Pa0012 40092, Krakow

Pa0012 40037, Lublin

Pa0012 40091, Nowa Sól

Pa0012 40044, Poznan

Pa0012 40090, Poznan

Pa0012 40041, Warsaw

Pa0012 40094, Warsaw

Pa0012 40097, Warsaw

Pa0012 40098, Warsaw

Pa0012 40118, Warsaw

Pa0012 40039, Wroclaw

Pa0012 40043, Wroclaw

Pa0012 40095, Wroclaw

Pa0012 20002, Moscow

Pa0012 20005, Moscow

Pa0012 20010, Moscow

Pa0012 20017, Moscow

Pa0012 20013, Petrozavodsk

Pa0012 20012, Ryazan

Pa0012 20016, Ryazan

Pa0012 20001, Saint Petersburg

Pa0012 20003, Saint Petersburg

Pa0012 20004, Saint Petersburg

Pa0012 20009, Saint Petersburg

Pa0012 20083, Saint Petersburg

Pa0012 20007, Saratov

Pa0012 20014, Ulyanovsk

Pa0012 20006, Vladimir

Pa0012 20008, Yaroslavl

Pa0012 20015, Yaroslavl

Pa0012 40045, A Coruña

Pa0012 40105, Córdoba

Pa0012 40102, Málaga

Pa0012 40101, Sabadell

Pa0012 40104, Santiago de Compostela

Pa0012 40049, Seville

Pa0012 40106, Seville

Pa0012 40099, Vigo

Pa0012 40109, Oxford

Pa0012 40116, Peterborough

Pa0012 40107, Wolverhampton

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04009499 - A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis | Biotech Hunter | Biotech Hunter